Research Paper Volume 15, Issue 24 pp 15134—15160
Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer
Figure 9. The high and low expression groups of COL10A1 were correlated with the ESTIMATE score, which includes the stromal score (indicating the presence of stromal cells in the tumor tissue), immune score (representing the infiltration of immune cells in the tumor tissue), and the purity of the tumor. Analysis of differences in stromal scores, immune scores and ESTIMATE scores between high and low COL10A1 expression groups in four cancers (KIRC, PRAD, KIRP, and UCEC) (A–D).